Ultomiris

Active Ingredient(s): Ravulizumab-cwvz
FDA Approved: * December 21, 2018
Pharm Company: * ALEXION PHARM

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ultomiris Overview

Ravulizumab (INN;[1] trade name Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, designed to bind to and prevent the activation of C5. This drug was developed by Alexion Pharmaceuticals, Inc.[2] It was engineered from eculizumab to have a longer-lasting effect.[3] It was approved by the US Food and Drug Administration in December 2018.[...

Read more Ultomiris Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ravulizumab

Recent Ultomiris Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Ultomiris: (1 result)

Sorted by National Drug Code

• 25682-022 Ultomiris 300 mg/30ml Intravenous Solution, Concentrate by Alexion Pharmaceuticals Inc.

Other drugs which contain Ravulizumab-cwvz or a similar ingredient: (1 result)

• RAVULIZUMAB